2007
Analysis of p53 protein expression levels on ovarian cancer tissue microarray using automated quantitative analysis elucidates prognostic patient subsets
Psyrri A, Kountourakis P, Yu Z, Papadimitriou C, Markakis S, Camp R, Economopoulos T, Dimopoulos M. Analysis of p53 protein expression levels on ovarian cancer tissue microarray using automated quantitative analysis elucidates prognostic patient subsets. Annals Of Oncology 2007, 18: 709-715. PMID: 17220511, DOI: 10.1093/annonc/mdl479.Peer-Reviewed Original ResearchConceptsDisease-free survivalOverall survivalP53 protein levelsP53 expression levelsPrognostic valueOvarian cancerBetter outcomesProtein levelsAdvanced stage ovarian cancerExpression levelsP53 protein expression levelsOvarian cancer tissue microarrayStage ovarian cancerOvarian cancer prognosisP53 levelsCancer tissue microarrayValuable prognostic markerP53 protein expressionSignificant predictor variablesProtein expression levelsObstetrics stageFIGO stagePatient subsetsMultivariable analysisPrognostic marker
2005
β-Catenin Functions Mainly as an Adhesion Molecule in Patients with Squamous Cell Cancer of the Head and Neck
Yu Z, Weinberger PM, Provost E, Haffty BG, Sasaki C, Joe J, Camp RL, Rimm DL, Psyrri A. β-Catenin Functions Mainly as an Adhesion Molecule in Patients with Squamous Cell Cancer of the Head and Neck. Clinical Cancer Research 2005, 11: 2471-2477. PMID: 15814622, DOI: 10.1158/1078-0432.ccr-04-2199.Peer-Reviewed Original ResearchConceptsSquamous cell cancerCyclin D1 levelsCell cancerNeck squamous cell cancerAdhesion moleculesD1 levelsDisease-free survivalIndependent prognostic factorLocal recurrence rateKaplan-Meier analysisMembranous expression patternLow cyclin D1Cancer tissue microarrayIncidence of mutationsProtein expression levelsMean followHazard ratioPrognostic factorsLocal recurrencePathologic dataCox regressionRecurrence rateMetastasis stageTissue microarrayBeta-catenin expressionMicrosatellite instability and gene mutations in transforming growth factor‐beta type II receptor are absent in small bowel carcinoid tumors
Kidd M, Eick G, Shapiro MD, Camp RL, Mane SM, Modlin IM. Microsatellite instability and gene mutations in transforming growth factor‐beta type II receptor are absent in small bowel carcinoid tumors. Cancer 2005, 103: 229-236. PMID: 15599934, DOI: 10.1002/cncr.20750.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBase Pair MismatchBase SequenceCarcinoid TumorCase-Control StudiesCohort StudiesDNA Mutational AnalysisFemaleGene Expression Regulation, NeoplasticGenomic InstabilityHumansIntestinal NeoplasmsIntestine, SmallMaleMicrosatellite RepeatsMiddle AgedMolecular Sequence DataMutationProbabilityPrognosisProtein Serine-Threonine KinasesReceptor, Transforming Growth Factor-beta Type IIReceptors, Transforming Growth Factor betaReverse Transcriptase Polymerase Chain ReactionSensitivity and SpecificityConceptsSmall bowel carcinoidsSmall bowel carcinoid tumorsCarcinoid tumorsGrowth factor beta type II receptorMicrosatellite instabilityMismatch repair genesType II receptorLiver metastasesNormal mucosaII receptorsBAT-26Carcinoid tumor metastasisVariable expressionMicrosatellite stable phenotypeRepair genes
2003
ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer.
Garcia-Rostan G, Zhao H, Camp RL, Pollan M, Herrero A, Pardo J, Wu R, Carcangiu ML, Costa J, Tallini G. ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer. Journal Of Clinical Oncology 2003, 21: 3226-35. PMID: 12947056, DOI: 10.1200/jco.2003.10.130.Peer-Reviewed Original ResearchConceptsThyroid carcinomaResult of diseasePoor prognosisRas mutationsTumor differentiationK-ras codon 13 mutationDifferentiated thyroid carcinomaCodon 13 mutationsAggressive cancer behaviorAggressive tumor phenotypeFollicular cell derivationN-ras mutationsClinicopathologic featuresIndependent predictorsUndifferentiated carcinomaThyroid cancerPoor survivalUndifferentiated tumorsPatientsCarcinomaActivating mutationsCancer behaviorSignificant associationTumorsRas tumors
2002
Tissue microarray‐based analysis shows phospho‐β‐catenin expression in malignant melanoma is associated with poor outcome
Kielhorn E, Provost E, Olsen D, D'Aquila TG, Smith BL, Camp RL, Rimm DL. Tissue microarray‐based analysis shows phospho‐β‐catenin expression in malignant melanoma is associated with poor outcome. International Journal Of Cancer 2002, 103: 652-656. PMID: 12494474, DOI: 10.1002/ijc.10893.Peer-Reviewed Original ResearchConceptsMalignant melanomaTissue microarray-based studyTissue microarray-based analysisWorse overall survivalDepth of invasionImmuno-histochemical analysisPhospho-specific antibodiesPhospho-β-catenin expressionOverall survivalMetastatic lesionsPrimary lesionPoor outcomePrognostic markerMelanomaUnique subsetNuclear stainingAntibodiesCatenin antibodyMicroarray-based analysisLesionsOutcomesCatenin expressionSer33/37/Thr41Microarray-based studiesHuman tissues